Clinical Trial Failure Risk: The success of Perspective Therapeutics' drug candidates, particularly its lead program VMT-α-NET, is highly dependent on positive and successful outcomes from ongoing and future clinical trials, which are inherently uncertain and frequently fail at various stages.

Regulatory Approval Challenges: Obtaining necessary regulatory approvals from the FDA and other international agencies for new drug candidates, especially novel radiopharmaceuticals, is a complex, time-consuming, and unpredictable process, with no guarantee of success.

Funding and Capital Needs: As a clinical-stage biotechnology company, Perspective Therapeutics will require substantial additional capital to fund ongoing research, clinical development, manufacturing, and potential commercialization efforts, and may not be able to obtain such funding on favorable terms or at all.